Enhanced Genomics secures £13.9m in funding from BGF, Parkwalk, and Meltwind to advance its therapeutic pipeline.
The financing round was backed by BGF, Parkwalk, and Meltwind to drive therapeutics discovery in autoimmune and other common diseases.
Enhanced Genomics operates a proprietary 3D multi-omics platform that maps genome-wide interactions to identify genetically validated drug targets for common diseases. The Cambridge-based biotechnology firm aims to accelerate pharmaceutical development and improve clinical success rates.
Enhanced Genomics has completed a funding round of £13.9m to advance its therapeutic pipeline and forge partnerships with pharmaceutical and biotechnology organisations. The investment was backed by BGF, Parkwalk, and Meltwind, bringing the company's total Series A financing to $19m. The capital will support the expansion of internal drug discovery programmes focused on autoimmune conditions and other prevalent medical needs.
Based in Cambridge, the biotechnology firm uses a 3D multi-omics platform to translate complex genetic data into causal biology. By pinpointing high-confidence targets on a genome-wide scale, the company seeks to enhance the efficiency and precision of pharmaceutical research.
From the founder
"Our founders have led the field by developing technology to map 3D interactions on a whole-genome scale, and integrating these data with comprehensive multi-omics datasets. We now have the technological capabilities to decipher the causal biology that drives complex and common genetic diseases, with the potential to develop truly effective new blockbuster therapies."
Dietrich Stephan
Chair at Enhanced Genomics
Use of funds
- 01Continue product development
- 02Fund research and development
- 03Fund acquisitions
Investors
Categories
About the company
Enhanced Genomics
Biotechnology company pioneering 3D multi-omics to identify drug targets for common diseases.